肾移植术后淋巴组织增生性疾病1例报道并文献复习

摘要
图/表
参考文献(15)
相关文章 (4)

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要淋巴组织增生性疾病是实体器官移植和造血干细胞移植术后出现的一种严重的并发症，其发病率低，临床表现多样且预后较差，目前对此疾病的认识仍较为有限，国内的相关病例报道也较少。本文报道1例肾移植术后发生淋巴组织增生性疾病的病例，并查阅相关文献，探讨了肾移植术后淋巴组织增生性疾病的分类、临床表现、治疗及预后。通过此病例，建议肾内科和泌尿外科医师加强对肾脏移植术后淋巴组织增生性疾病发病的关注，并进行及时有效的处理。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	李颖
	刘航
	韩猛虎
	卫淑润
	张鹏
	白保亮
	王茜
	常一阁

关键词 ：肾移植, 淋巴组织增生性疾病, 小肠破裂, 利妥昔单抗, 病例报告

Abstract：Lymphoproliferative disorders are a serious complication after solid organ or hematopoietic cell transplantation.It has low morbidity,versatile clinical manifestations and bad prognosis.At present,the understanding of this disease is still relatively limited,and there are also fewer such reports.This article reports a case of lymphoproliferative disorders after kidney transplantation and consults related literature to discuss the classification,clinical manifestations,treatment and prognosis of lymphoproliferative disorders after kidney transplantation.Through this case,it is recommended that nephrologists and urologist should pay attention to lymphoproliferative disorders after kidney transplantation and make a effective therapy.

Key words： Kidney transplantation Lymphoproliferative disorders Small intestinal rupture Rituximab Case report

通讯作者: 刘航（1965-），女，副主任医师，研究方向：血液净化治疗、肾脏及移植肾病理诊断、肾移植术前术后处理、肾移植术后长期并发症的治疗与预防

作者简介: 李颖（1989-），女，硕士，研究方向：肾移植术后长期并发症的治疗与预防

引用本文:

李颖；刘航；韩猛虎；卫淑润；张鹏；白保亮；王茜；常一阁. 肾移植术后淋巴组织增生性疾病1例报道并文献复习[J]. 中国当代医药, 2020, 27(34): 221-224.
LI Ying； LIU Hang； HAN Meng-hu； WEI Shu-run； ZHANG Peng； BAI Bao-liang； WANG Qian；CHANG Yi-ge. Post-transplant lymphoproliferative disorders following renal transplantation：a case report and literatures review. 中国当代医药, 2020, 27(34): 221-224.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2020/V27/I34/221

[1]	Hart A，Gustafson SK，Skeans MA，et al.OPTN/SRTR 2015 Annual Data Report：Early effects of the new kidney allocation system[J].Am J Transplant，2017，17 Suppl 1：543-564.
[2]	Ferreiro JF，Morscio J，Dierickx D，et al.EBV-positive and EBV-negative posttransplant diffuse large B cell lymphomas have distinct genomic and transcrip-tomic features[J].Am J Transplant，2016，16（2）：414-425.
[3]	Kotton CN，Huprikar S，Kumar D.Transplant infectious diseases：a review of the scientific registry of transplant recipients published data[J].Am J Transplant，2017，17（6）：1439-1446.
[4]	Swerdlow SH，Campo E，Pileri SA，et al.The 2016 revision of the World Health Organization classification of lymphoid neoplasms[J].Blood，2016，127（20）：2375-2390.
[5]	Inayat F，Hassan GU，Tayyab GUN，et al.Post-transplantation lymphoproliferative disorder with gastrointestinal involvement[J].Ann Gastroenterol，2018，31（2）：248-251.
[6]	Dunn C，Nguyen HP，Patel V，et al.Primary cutaneous Hodgkinlike polymorphic post-transplant lymphoproliferative disorder[J].J Cutan Pathol，2019，46（5）：358-362.
[7]	Mouchli MA，Singh S，Loftus EV Jr，et al.Risk factors and outcomes of de novo cancers （excluding nonmelanoma skin cancer） after liver transplantation for primary sclerosing cholangitis[J].Transplantation，2017，101（8）：1859-1866.
[8]	Mahale P，Shiels MS，Lynch CF，et al.Incidence and outcomes of primary central nervous system lymphoma in solid organ transplant recipients[J].Am J Transplant，2018，18（2）：453-461.
[11]	Spagnoletti G，Salerno MP，Calia R，et al.Thymoglobuline plus basiliximab a mixed cocktail to start?[J].Transpl Immunol，2017，43-44：1-2.
[9]	Allen UD，Preiksaitis JK，AST Infectious Diseases Community of Practice.Epstein-Barr virus and posttransplant lymphoproliferative disorder in solid organ transplantation[J].Am J Transplant，2013，13 Suppl 4：107-120.
[10]	AlDabbagh MA，Gitman MR，Kumar D，et al.The role of antiviral prophylaxis for the prevention of Epstein-Barr virus-associated posttransplant lymphoproliferative disease in solid organ transplant recipients：a systematic review[J].Am J Transplant，2017，17（3）：770-781.
[12]	Martinez-Calle N，Alfonso A，Rifon J，et al.First-line use of rituximab correlates with increased overall survival in late posttransplant lymphoproliferative disorders：retrospective，single-centre study[J].Eur J Haematol，2017，98（1）：38-43.
[13]	Trappe RU，Dierickx D，Zimmermann H，et al.Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International，Prospective，Multicenter PhaseⅡTrial[J].J Clin Oncol，2017，35（5）：536-543.
[14]	Francis A，Johnson DW，Craig JC，et al.Incidence and predictors of cancer following kidney transplantation in childhood[J].Am J Transplant，2017，17（10）：2650-2658.
[15]	Eshraghian A，Imanieh MH，Dehghani SM，et al.Posttransplant lymphoproliferative disorder after liver transplantation：Incidence，long-term survival and impact of serum tacrolimus level[J].World J Gastroenterol，2017，23（7）：1224-1232.